Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus with a hemoglobin A1c (HbA1c) greater than or equal to (\>=) 6.5 percent (%) and less than or equal to (\<=) 12.0%, with an estimated glomerular filtration rate (eGFR) of \>= 30 milliliter (mL)/minute (min)/1.73meter (m)\^2 and less than (\<) 90 mL/min/1.73 m\^2~* Participants need to be on a stable maximum tolerated labeled daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) for at least 4 weeks prior to randomization~* Must have a urine albumin to creatinine ratio (UACR) of greater than (\>) 300 milligram (mg)/gram (g) and \<= 5000 mg/g~Exclusion Criteria:~* History of diabetic ketoacidosis or type 1 diabetes mellitus~* History of hereditary glucose-galactose malabsorption or primary renal glucosuria~* Renal disease that required treatment with immunosuppressive therapy~* Known significant liver disease~* Current or history of New York Heart Association (NYHA) Class IV heart failure~* Blood potassium level \>5.5 millimole (mmol)/liter (L) during Screening

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Canagliflozin 100 mg (Type: EXPERIMENTAL): Each participant will receive 100 mg of canagliflozin once daily
- Placebo (Type: PLACEBO_COMPARATOR): Each participant will receive matching placebo once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).